Hlorzoksazon |
(IUPAC) ime |
5-hloro-3H-benzooksazol-2-on |
Klinički podaci |
Robne marke | Parafonforte |
AHFS/Drugs.com | Monografija |
MedlinePlus | a682577 |
Identifikatori |
CAS broj | 95-25-0 |
ATC kod | M03BB03 |
PubChem[1][2] | 2733 |
DrugBank | DB00356 |
ChemSpider[3] | 2632 |
UNII | H0DE420U8G Y |
KEGG[4] | D00771 Y |
ChEBI | CHEBI:3655 Y |
ChEMBL[5] | CHEMBL1371 Y |
Hemijski podaci |
Formula | C7H4ClNO2 |
Mol. masa | 169,565 g/mol |
SMILES | eMolekuli & PubHem |
InChI | InChI=1S/C7H4ClNO2/c8-4-1-2-6-5(3-4)9-7(10)11-6/h1-3H,(H,9,10) Y Key: TZFWDZFKRBELIQ-UHFFFAOYSA-N Y | |
Farmakokinetički podaci |
Bioraspoloživost | dobro je apsorbovan |
Vezivanje za proteine plazme | 13–18% |
Metabolizam | hepatic |
Poluvreme eliminacije | 1,1 h |
Izlučivanje | urine (<1%) |
Farmakoinformacioni podaci |
Trudnoća | ? |
Pravni status | |
Način primene | oralno |
Hlorzoksazon je centralno delujući miorelaksant, koji se koristi za tretiranje mušićnih spazama i rezultirajućeg bola ili neprijatnosti. On deluje na kičmenu moždinu. Hlorzoksazon je u prodaji pod imenima Muscol ili Parafon Forte, kao kombinacija sa acetaminofenom (Paracetamolom). Moguće nuspojave su: vrtoglavica, nepromišljenost, slabost, mučnina, povraćanje, i disfunkcija jetre.
Hemija
Hlorzoksazon, 5-hloro-2-benzoksazolion, se može sintetisati reakcijom heterciklizacije 2-amino-4-hlorofenola sa fosgenom.
Reference
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
Literatura
- D.F. Marsh, U.S. Patent 2.895.877 (1959).
- Dong DL, Luan Y, Feng TM, Fan CL, Yue P, Sun ZJ, Gu RM, Yang BF. (2006). „Chlorzoxazone inhibit contraction of rat thoracic aorta”. Eur J Pharmacol 545 (2–3): 161–6. DOI:10.1016/j.ejphar.2006.06.063. PMID 16859676.
- Park J, Kim K, Park P, Ha J (2006). „Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe”. J Clin Pharmacol 46 (1): 109–14. DOI:10.1177/0091270005282635. PMID 16397290.
- Wan J, Ernstgård L, Song B, Shoaf S (2006). „Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats”. J Pharm Pharmacol 58 (1): 51–61. DOI:10.1211/jpp.58.1.0007. PMC 1388188. PMID 16393464.
Spoljašnje veze
| Portal Medicina |
| Portal Hemija |
- PARAFON DSC (chlorzoxazone) tablet, Daily Med, U.S. National Library of Medicine